There has been new research announced in an article on Bloomberg's Business Week that discusses mutated genes and the impact on the likelihood of getting ovarian cancer. In this arena, neurotoxicity in therapies has also been a constant bane in the side of researchers, drug manufacturers (and, subsequently, patients). Access Pharmaceuticals is making strides with their lead oncology drug, ProLindac, in the overall fight against the disease and showing promising data with regards to eliminating neurotoxic side effects.